Testing QLC2519 with chemotherapy for pediatric sarcoma
Part of Blood & lymphatic clinical trials.
This trial tests a new drug (QLC2519) given alongside a standard chemotherapy regimen called VDC/IE for children and teens with sarcoma. The goal is to see if it can help treat their cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The patient must be between birth and 18 years old.
- They must have been diagnosed with sarcoma (cancer of bone or soft tissue).
- They must be able to receive at least 3 cycles of the VDC/IE chemotherapy regimen.
- They must have adequate blood counts, liver and kidney function before starting chemotherapy.
- They must not have had chemotherapy or radiation therapy before.
- Females who have started menstruating must not be pregnant or breastfeeding, and all patients of childbearing potential must use effective contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two new drugs (QLS31905 and/or QL1706) with chemotherapy for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a new combination of an immunotherapy drug (QL1706) with standard chemotherapy for people whose lung cancer has a specific genetic change (SMARCA4 deficiency). The goal is to see if this combination can shrink tumors and improve outcomes for this particular group of patients.
This trial tests a treatment plan for children with newly diagnosed acute lymphoblastic leukemia (ALL) that is considered standard-risk. It aims to see if the treatment is effective and safe.
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to chemotherapy can help young people whose bone or soft tissue sarcoma has come back or hasn't responded to previous treatment.
This trial tests a new combination of drugs for people with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and improve outcomes.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
Hear when a new Neutropenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.